News - Array Biopharma Inc.
BOULDER, Colo. and THOUSAND OAKS, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Array BioPharma Inc.
Array BioPharma Inc. (NASDAQ: ARRY) today reported financial results for the first quarter of fiscal 2009. Array reported revenue of $5.7 million for the first quarter of fiscal 2009, compared to revenue of $6.6 million for the same period in fiscal 2008.
Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from a Phase 2 acute inflammatory dental pain study evaluating the analgesic efficacy of ARRY-797, a small molecule p38 inhibitor, at the 2008 ACR/ARHP Annual Scientific Meeting in San Francisco, Calif.
Array BioPharma Inc. (Nasdaq: ARRY) today announced the presentation of preclinical data on a novel small molecule glucokinase activator (GKA), ARRY-403, a drug for the treatment of Type 2 diabetes.